Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Amortizatization of Intangibles (2016)

Historic Amortizatization of Intangibles for United Therapeutics (UTHR) over the last 8 years, with Q2 2016 value amounting to -$100000.0.

  • United Therapeutics' Amortizatization of Intangibles rose 7500.0% to -$100000.0 in Q2 2016 from the same period last year, while for Jun 2016 it was -$1.0 million, marking a year-over-year increase of 7167.17%. This contributed to the annual value of -$2.1 million for FY2015, which is 5924.3% up from last year.
  • According to the latest figures from Q2 2016, United Therapeutics' Amortizatization of Intangibles is -$100000.0, which was up 7500.0% from -$200000.0 recorded in Q1 2016.
  • In the past 5 years, United Therapeutics' Amortizatization of Intangibles ranged from a high of -$100000.0 in Q2 2016 and a low of -$1.6 million during Q1 2014
  • Over the past 5 years, United Therapeutics' median Amortizatization of Intangibles value was -$1.0 million (recorded in 2013), while the average stood at -$931555.6.
  • As far as peak fluctuations go, United Therapeutics' Amortizatization of Intangibles tumbled by 5944.33% in 2014, and later skyrocketed by 8000.0% in 2016.
  • United Therapeutics' Amortizatization of Intangibles (Quarter) stood at -$1.3 million in 2012, then fell by 10.3% to -$1.4 million in 2013, then grew by 27.8% to -$1.0 million in 2014, then soared by 74.32% to -$266000.0 in 2015, then skyrocketed by 62.41% to -$100000.0 in 2016.
  • Its Amortizatization of Intangibles was -$100000.0 in Q2 2016, compared to -$200000.0 in Q1 2016 and -$266000.0 in Q4 2015.